• pH-Mediated Interactions of Ribociclib: QbD Insights for Onc

  2026-05-08

  This article explores a recent Quality by Design (QbD) investigation into the pH-dependent solubility and absorption of ribociclib, a CDK4/6 inhibitor used in HER2-positive metastatic breast cancer. The study demonstrates that acid-reducing agents do not significantly impact ribociclib’s solubility or absorption, informing protocol design for combination therapies and translational research.

• Antimycin A4: Dual ATP-Citrate Lyase & Mitochondrial Inhibit

  2026-05-07

  Antimycin A4 is a Streptomyces-derived ATP-citrate lyase inhibitor and mitochondrial respiratory chain blocker. It is primarily used as a research tool for dissecting fatty acid and cholesterol biosynthesis as well as eukaryotic energy metabolism. Its dual mechanism and specificity make it essential for metabolic and mitochondrial studies.

• Patient-Derived Gastric Cancer Assembloids Reveal Stromal Mo

  2026-05-07

  This study introduces a robust patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations, better replicating tumor microenvironment complexity. The model enables nuanced investigation of tumor–stroma interactions, gene expression, and drug response, enhancing the predictive power of preclinical testing for personalized therapy.

• Protease Inhibitor Cocktail: Optimizing Protein Stability Wo

  2026-05-06

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) by APExBIO delivers uncompromised protein stability during cell and tissue extraction, even in demanding OXPHOS and kinase assay workflows. This article reveals setup best practices, troubleshooting insights, and evidence-based protocol enhancements for maximizing intact protein recovery in complex biological samples.

• Gamithromycin (ML-1709460): PK/PD-Driven Innovation in Bovin

  2026-05-06

  Explore how Gamithromycin (ML-1709460) redefines respiratory infection models with advanced PK/PD integration and evidence-based dosing. This article uniquely bridges pharmacodynamic insights with practical protocol guidance for translational research.

• Sildenafil Citrate: Precision cGMP-PDE5 Inhibition in Vascul

  2026-05-05

  Sildenafil Citrate from APExBIO empowers vascular and proteoform-centric research with unmatched selectivity and solubility. This guide details advanced experimental designs, troubleshooting strategies, and actionable workflow enhancements, leveraging the latest proteomics insights for reproducible, high-impact results.

• Mdivi-1 as a Selective DRP1 Inhibitor: Precision in Apoptosi

  2026-05-05

  Discover how Mdivi-1, a selective DRP1 inhibitor, uniquely empowers apoptosis and mitochondrial dynamics research. This article offers a deeper mechanistic perspective and practical assay guidance not found in existing resources.

• TMRE Mitochondrial Membrane Potential Assay Kit: Sodium, NEC

  2026-05-04

  Discover how the TMRE mitochondrial membrane potential assay kit enables advanced detection of mitochondrial dysfunction, with new insights from sodium-driven NECSO mechanisms. Explore nuanced, evidence-based guidance for translational research and apoptosis studies.

• Trichostatin A for Epigenetic Regulation: Protocols & Insigh

  2026-05-04

  Trichostatin A (TSA) is redefining cancer epigenetics by enabling precise, reproducible modulation of histone acetylation and cell cycle arrest. This article delivers actionable protocols, troubleshooting guidance, and comparative insights to maximize TSA’s impact in advanced oncology and differentiation research workflows.

• Alternariol Induces Hepatic Stellate Cell Activation in Fibr

  2026-05-03

  This study demonstrates that Alternariol (AOH) and related Alternaria toxins directly induce hepatic stellate cell activation and transdifferentiation, a critical step in liver fibrosis. Using integrated lncRNA-mRNA omics and mechanistic pathway analysis, the authors illuminate the molecular events linking mycotoxin exposure to hepatotoxicity, with implications for food safety and detoxification strategies.

• Actinomycin D in Epitranscriptomic Research: Precision Tools

  2026-05-02

  Explore Actinomycin D’s pivotal role in dissecting m6A-mediated gene regulation and ferroptosis pathways in cancer research. This article offers a deep dive into advanced applications, protocol parameters, and unique insights for experimental design.

• Mubritinib (TAK 165): Data-Driven Solutions for Cancer Biolo

  2026-05-02

  This article provides scenario-driven, evidence-based guidance for deploying Mubritinib (TAK 165) (SKU B1543) in cell viability and cytotoxicity assays. Readers will find actionable answers to real-world experimental challenges, protocol optimization tips, and a rigorous comparison of sourcing options, ensuring reproducibility and data integrity for advanced cancer biology research.

• Doxorubicin (Adriamycin): Precision Chemotherapy for Model S

  2026-05-01

  Explore the scientific rigor behind Doxorubicin (Adriamycin) as a reference chemotherapeutic agent for solid tumors and hematologic malignancy research. Discover how protocol optimization and mechanistic insights elevate its value in advanced cancer model systems—a perspective not found in standard Doxorubicin guides.

• Phosphatase Inhibitor Cocktail (2 Tubes, 100X): Practical Gu

  2026-04-30

  The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) preserves protein phosphorylation during sample preparation by inhibiting both serine/threonine and tyrosine phosphatases. It is recommended for workflows where accurate phosphorylation state analysis is critical, such as immunoblotting and kinase assays, but is not intended for diagnostic or clinical applications.

• Naloxone Hydrochloride: Strategic Mechanisms in Translationa

  2026-04-30

  This thought-leadership article bridges mechanistic insights with strategic guidance for translational researchers exploring naloxone hydrochloride. We dissect the compound’s multifaceted biology, anchor new findings in opioid and neural stem cell research, and provide actionable recommendations for advancing opioid receptor antagonist studies. By benchmarking APExBIO’s high-purity formulation against prevailing standards, we chart a differentiated course for innovation across addiction, neuroregeneration, and immune modulation.

408 records 16/28 page Previous Next First page 上5页 1617181920 下5页 Last page